Adjuvant rituximab and elevated intratumoural CD8 expression are associated with sustained disease control after radiotherapy in a randomised trial of systemic therapy in early-stage follicular lymphoma.
MacManus MP, Seymour JF, Tsang H, Fisher R, Keane C, Sabdia MB, Law SC, Gunawardana J, Nath K, Kazakoff SH, Marques-Piubelli ML, Duenas DE, Green MR, Roos D, O'Brien P, McCann A, Tsang R, Davis S, Christie D, Cheah C, Amanuel B, Cochrane T, Butler J, Johnston A, Shanavas M, Li L, Vajdic C, Kridel R, Shelton V, Hershenfield S, Baetz T, Lebrun D, Johnson N, Brodtkorb M, Ludvigsen M, d'Amore F, Thompson ER, Blombery P, Gandhi MK, Tobin JWD.
MacManus MP, et al. Among authors: blombery p.
EBioMedicine. 2024 Dec;110:105468. doi: 10.1016/j.ebiom.2024.105468. Epub 2024 Dec 3.
EBioMedicine. 2024.
PMID: 39631145
Free PMC article.
Clinical Trial.